Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Dec 15.

Published in final edited form as: Clin Cancer Res. 2011 Oct 28;17(24):7634–7644. doi: 10.1158/1078-0432.CCR-11-1677

Figures 4a and b: Change in SUV_mean and SUV_max (normalized to baseline) by clinical benefit group. Note that the 4/2 and 2/1 schedules are combined so that the abscissa is scaled to sunitinib exposure (and scan time points) instead of time. CB, clinical benefit. NCB, no clinical benefit. ccRCC, clear cell renal cell carcinoma.

Figures 4a and b: Change in SUV_mean and SUV_max (normalized to baseline) by clinical benefit group. Note that the 4/2 and 2/1 schedules are combined so that the abscissa is scaled to sunitinib exposure (and scan time points) instead of time. CB, clinical benefit. NCB, no clinical benefit. ccRCC, clear cell renal cell carcinoma.